An androgenetic alopecia remedy based on marine collagen peptide-incorporated dissolving microneedles

Int J Pharm. 2024 Jan 25:650:123629. doi: 10.1016/j.ijpharm.2023.123629. Epub 2023 Nov 20.

Abstract

Given that current androgenetic alopecia (AGA) medications have adverse effects such as sexual dysfunction and drug dependence, researchers are actively exploring natural bioactive ingredients and innovative approaches (e.g., transdermal drug delivery systems) to effectively combat hair loss with minimal side effects. Herein, we develop a new transdermal drug delivery system incorporating globefish skin collagen peptides with dissolving microneedles (GSCPs-MNs) for hair regrowth. These microneedles generate skin micro-wounds upon application, which not only improves the efficiency of bioactive ingredients delivery, but also stimulates signals involved in hair follicle (HF) regeneration. Our in vivo study shows that minimally invasive implanted GSCPs-MNs are more effective than topical GSCPs in reducing inflammation and promoting collagen formation. Additionally, the upregulation of vascular markers including VEGF and CD31 alongside the downregulation of TNF-α, IL-1β, and malondialdehyde (MDA) index indicate that GSCPs-MNs can significantly alleviate inflammation and oxidation, as well as promoting vascularization and HF functionalization. Overall, our findings suggest that GSCPs-MNs can effectively promote hair regrowth in AGA mice, which offer excellent prospects for the development of new therapeutics and cosmetic supplements for hair loss, along with the combined drug delivery optimization, which could alleviate hair loss in patients with AGA.

Keywords: Androgenic alopecia; Globefish skin collagen peptides; Hair regrowth; Microneedles.

MeSH terms

  • Alopecia* / drug therapy
  • Animals
  • Collagen
  • Hair*
  • Humans
  • Inflammation / drug therapy
  • Mice
  • Peptides / pharmacology
  • Pharmaceutical Vehicles

Substances

  • Peptides
  • Pharmaceutical Vehicles
  • Collagen